Please assess the completion status of the following clinical trial:

Trial Title: Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 50years of age with End stage renal disease on dialysis (both hemodialysis and peritoneal dialysis).~* Scheduled to receive pneumococcal vaccine either after 5years of previous vaccination or starting vaccination as part of standard care during the study period~Exclusion Criteria:~* History of S. pneumoniae infection within the last 5 years~* Vaccinated with an influenza- or diphtheria-containing vaccine within the last 6 months~* History of any severe adverse reaction associated with a vaccine~* Received gamma-globulins within the previous 6 months~* Known or suspected HIV or on immunosuppressive medications.~* Functional or anatomic asplenia~* serious chronic medical condition

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.

Based on this trial design, predict the completion outcome and termination type (if applicable).